Life Sciences Sector Policy Delivery

The government and the UK life sciences industry have launched a Joint Taskforce to drive innovation in the UK’s commercial environment for medicines. 

As part of the delivery of the 10 Year Health Plan and Life Science Sector Plan, the government has established a sprint process with the pharmaceutical sector to consider options for accelerating progress towards the government’s ambitions for the UK to be the third most important Life Science economy by 2035.

This process will not replace the formal voluntary scheme negotiations, which are expected to commence in 2027 and conclude in 2028, but will act as a precursor to developing options for a future scheme and to examining the broader medicines pricing system.  

The process will involve key agencies such as NHS England and the National Institute for Health and Care Excellence (NICE), and engage with charitable and patient groups to ensure a broad range of views are considered.

The Taskforce aims to report back to ministers and industry leaders and, where appropriate, will be followed by pilot schemes and idea rollouts as early as September 2026.

TAGS
  • Medicines pricing
  • Pricing
  • Access

Last modified: 25 March 2026

Last reviewed: 25 March 2026

The ABPI exists to make the UK the best place in the world to research, develop and use new medicines. We represent companies of all sizes who invest in discovering the medicines of the future. 

Our members supply cutting edge treatments that improve and save the lives of millions of people. We work in partnership with Government and the NHS so patients can get new treatments faster and the NHS can plan how much it spends on medicines. Every day, we partner with organisations in the life sciences community and beyond to transform lives across the UK.